Online inquiry

IVTScrip™ mRNA-Anti-MADCAM1, PF-00547659(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13069MR)

This product GTTS-WQ13069MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets MADCAM1 gene. The antibody can be applied in Crohn's disease (CD) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_130760.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 8174
UniProt ID Q13477
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MADCAM1, PF-00547659(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ13069MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9247MR IVTScrip™ mRNA-Anti-MUC1, IMMU-107(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA IMMU-107
GTTS-WQ10609MR IVTScrip™ mRNA-Anti-PDCD1, LY3300054(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA LY3300054
GTTS-WQ3094MR IVTScrip™ mRNA-Anti-FASLG, APG-101(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA APG-101
GTTS-WQ9371MR IVTScrip™ mRNA-Anti-IL2R, Interleukin 2(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA Interleukin 2
GTTS-WQ9982MR IVTScrip™ mRNA-Anti-env, KD-247(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA KD-247
GTTS-WQ1403MR IVTScrip™ mRNA-Anti-MUC16, ACA125(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ACA125
GTTS-WQ6809MR IVTScrip™ mRNA-Anti-STEAP1, DSTP-3086S(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA DSTP-3086S
GTTS-WQ7854MR IVTScrip™ mRNA-Anti-RTN4, GSK-1223249(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA GSK-1223249
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW